Lung Cancer Liquid Biopsy Market (By Sample Type; By Biomarker; By Technology; By End-use; By Clinical Application; By Product) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Lung Cancer Liquid Biopsy Market Size and Growth

The global lung cancer liquid biopsy market size was estimated at around USD 0.98 billion in 2023 and it is projected to hit around USD 3.43 billion by 2033, growing at a CAGR of 13.35% from 2024 to 2033.

Key Pointers

• North America led the global market with the largest market share of 51% in 2023.
• By End-use, the hospitals and laboratories segment generated the maximum market share in 2023.
• By End-use, the specialty clinics segment is projected to register the fastest CAGR from 2024 to 2033.
• By Biomarker, the circulating nucleic acids segment contributed the largest market share in 2023.
• By Technology, the multi-gene parallel analysis (NGS) segment held the largest revenue share in 2023 and is projected to grow at the fastest CAGR from 2024 to 2033.
• By Clinical Application, the therapy selection segment captured the maximum market share in 2023.
• BY Product, the instruments segment held the largest revenue share in 2023 and is projected to achieve the fastest CAGR during the forecast period

Lung Cancer Liquid Biopsy Market Overview

The lung cancer liquid biopsy market is experiencing significant growth and transformation, driven by advances in technology, rising incidences of lung cancer, and an increasing demand for non-invasive diagnostic methods. Liquid biopsy, a less invasive alternative to traditional tissue biopsy, uses a simple blood sample to detect cancer-related biomarkers, providing a promising approach for early diagnosis, monitoring, and treatment of lung cancer.

Lung Cancer Liquid Biopsy Market Growth Factors

The growth of the lung cancer liquid biopsy market is driven by the technological advancements in molecular diagnostics, such as next-generation sequencing (NGS) and digital PCR, have significantly improved the accuracy and efficiency of liquid biopsy tests, making them more reliable for detecting cancer biomarkers. Additionally, the rising incidence of lung cancer globally has increased the demand for early and minimally invasive diagnostic methods. Liquid biopsy offers a non-invasive alternative to traditional tissue biopsies, which are often risky and uncomfortable for patients. Moreover, the trend towards personalized medicine, where treatments are tailored based on individual genetic profiles, is also driving market growth. Liquid biopsy enables precise monitoring of tumor mutations and treatment responses, thereby enhancing the effectiveness of targeted therapies. These factors collectively contribute to the expanding adoption and development of liquid biopsy technologies in the lung cancer diagnostics market.

U.S. Lung Cancer Liquid Biopsy Market Size 2024 to 2033

The U.S. lung cancer liquid biopsy market was estimated at USD 0.34 billion in 2023 and it is expected to surpass around USD 1.22 billion by 2033, poised to grow at a CAGR of 13.62% from 2024 to 2033.

In the United States, lung cancer liquid biopsy dominated the revenue share in North America. The country benefits from a well-established healthcare system equipped with cutting-edge technology, facilitating early detection and diagnosis of lung cancer. Liquid biopsies, which involve analyzing circulating tumor DNA (ctDNA) in the blood, offer a less invasive alternative to traditional tissue biopsies and can be performed more frequently. Additionally, heightened awareness about lung cancer and its early detection, driven by public health campaigns, medical conferences, and educational programs, prompts more patients and healthcare providers to opt for liquid biopsies as a diagnostic tool.

North America emerged as the dominant market, capturing approximately 51% of the revenue share in 2023. The region contends with a higher prevalence of smoking compared to others, a major risk factor for lung cancer, consequently leading to a greater incidence of the disease. With its advanced medical infrastructure, including specialized equipment and well-trained professionals, North America is well-equipped to conduct lung cancer biopsies. Moreover, the region generally boasts better access to healthcare services, including lung cancer screening and diagnostic procedures such as biopsies, potentially resulting in increased detection of lung cancer cases. These factors collectively contribute to a heightened demand for lung cancer biopsies in North America compared to other regions.

Asia Pacific is poised to witness significant growth from 2024 to 2033. Lung cancer ranks among the most common cancers in this region, with notably high incidence rates in countries like China, India, and Japan. This increased prevalence naturally translates into a greater demand for diagnostic procedures such as biopsies. Tobacco use, particularly smoking, amplifies the risk of lung cancer, necessitating more biopsies for diagnosis and treatment. Additionally, air pollution poses a significant concern in the region, with elevated levels of particulate matter and other pollutants contributing to respiratory issues and lung cancer risk. Consequently, there is a heightened need for lung cancer screening and biopsies to address these challenges.

Lung Cancer Liquid Biopsy Market Trends:

• Advancements in Technology: Continuous improvements in genomic technologies such as next-generation sequencing (NGS) and digital PCR are enhancing the accuracy and sensitivity of liquid biopsies, making them more effective in detecting and analyzing cancer biomarkers.
• Increased Adoption of Non-Invasive Diagnostics: There is a growing preference for non-invasive diagnostic methods among patients and healthcare providers. Liquid biopsies offer a safer and less painful alternative to traditional tissue biopsies, facilitating more frequent monitoring of disease progression and treatment response.
• Rising Incidence of Lung Cancer: The increasing prevalence of lung cancer globally is driving the demand for early and accurate diagnostic methods. Liquid biopsies provide a means for early detection, which is crucial for improving patient outcomes.
• Growth of Personalized Medicine: Liquid biopsies are integral to the development of personalized treatment plans. By analyzing specific genetic mutations in tumors, these tests enable the customization of therapies to better target individual cancers, enhancing treatment efficacy and reducing side effects.

Lung Cancer Liquid Biopsy Market Restraints:

• High Costs: The cost of advanced liquid biopsy technologies, including next-generation sequencing (NGS) and digital PCR, can be prohibitively high. This limits accessibility for patients and healthcare providers, particularly in lower-income regions.
• Limited Sensitivity and Specificity: While liquid biopsies have advanced significantly, they may still struggle to detect low levels of circulating tumor DNA (ctDNA) or other biomarkers, especially in early-stage cancers. This can lead to false negatives, impacting the effectiveness of early diagnosis.
• Regulatory Hurdles: Obtaining regulatory approvals for new liquid biopsy tests can be a lengthy and complex process. Stringent regulations and the need for extensive clinical validation can delay the commercialization of innovative diagnostic tools.
• Limited Awareness and Acceptance: There is still a lack of widespread awareness and acceptance of liquid biopsy technologies among some healthcare providers and patients. Traditional tissue biopsies remain the standard in many clinical settings, slowing the adoption of liquid biopsies.

Sample Type Insights

The blood sample-based segment led the market in 2023, capturing a revenue share of over 71%. This dominance is due to its non-invasive nature, repeatability, real-time monitoring capabilities, early detection, and cost-effectiveness. Blood sample-based biopsy tests can be conducted multiple times during a patient’s treatment without causing additional harm or discomfort. Additionally, liquid biopsies offer real-time updates on the patient’s condition, as they can be performed at any stage of the disease and throughout the treatment process.

End-use Insights

The hospitals and laboratories segment captured the largest revenue share in 2023. These institutions employ specialized medical professionals, including oncologists, pathologists, and radiologists, who possess the expertise necessary to accurately perform and interpret biopsies. Additionally, hospitals and laboratories have access to advanced equipment and technologies essential for biopsy procedures and subsequent analyses. These facilities adhere to stringent quality control measures and safety protocols to ensure precise and reliable results. They also follow well-established protocols for handling biological samples, minimizing contamination risks, and maintaining sample integrity.

The specialty clinics segment is projected to register the fastest CAGR from 2024 to 2033. Specialty clinics focus on specific diseases or medical conditions, such as lung cancer, enabling them to develop a comprehensive understanding of the disease, its diagnosis, and treatment options. These clinics prioritize patient needs and preferences, offering personalized care and support tailored to each individual. This patient-centric approach can lead to increased patient satisfaction and improved adherence to treatment plans, thereby contributing to the growth of specialty clinics.

Biomarker Insights

The circulating nucleic acids segment accounted for the largest revenue share in 2023. Circulating nucleic acids, especially circulating tumor DNA (ctDNA), can be detected at very low concentrations in blood samples, even in the early stages of cancer. Early detection of lung cancer significantly increases the chances of successful treatment and improves patient survival rates. By analyzing these circulating nucleic acids, healthcare providers can make informed decisions about treatment adjustments and more effectively monitor the patient’s response to therapy. Additionally, ctDNA carries valuable genetic and molecular information about the cancer, which can be used to identify specific mutations and biomarkers associated with lung cancer. This information helps healthcare professionals develop personalized treatment strategies and targeted therapies.

The exosomes/microvesicles segment is expected to register the fastest CAGR from 2024 to 2033. Exosomes and microvesicles can be isolated from a simple blood sample, making them ideal for liquid biopsy applications. These biomarkers reflect changes in the tumor microenvironment and cancer progression. Monitoring the levels of these vesicles in blood samples helps healthcare providers track disease progression and response to treatment, enabling timely adjustments to treatment plans.

Technology Insights

The multi-gene parallel analysis (NGS) segment dominated the market in 2023 and is projected to grow at the fastest CAGR from 2024 to 2033. This growth is driven by NGS's ability to comprehensively analyze multiple genes, detect various mutations, identify actionable targets for personalized treatment, enable early detection, and monitor disease progression and treatment response. NGS allows for the simultaneous analysis of numerous genes, providing a deeper understanding of the genetic and molecular alterations involved in lung cancer. It can detect a wide range of genetic alterations, including single nucleotide variations, insertions, deletions, and copy number variations.

The single gene analysis (PCR microarrays) segment is anticipated to witness growth during the forecast period. The increasing use of PCR microarrays in lung cancer screening is expected to drive the growth of this segment. PCR microarrays are cost-effective compared to other genetic analysis methods, such as Sanger sequencing or next-generation sequencing (NGS), making them more accessible to patients and healthcare systems.

Clinical Application Insights

The therapy selection segment held the largest revenue share in 2023. Different therapies carry varying levels of risk and potential side effects. Healthcare professionals can mitigate the risks associated with biopsy procedures by selecting the most appropriate treatment for each patient. Therapy selection in lung cancer biopsy screening is essential for ensuring accurate diagnosis, minimizing risks, delivering personalized treatment, optimizing resource allocation, and prioritizing patient comfort.

The early cancer screening segment is projected to achieve the fastest CAGR from 2024 to 2033. Detecting lung cancer at an early stage significantly improves the likelihood of successful treatment and higher survival rates. Early-stage lung cancer is often more treatable, with a wider range of treatment options available to patients

Product Insights

The instruments segment held the largest revenue share in 2023 and is projected to achieve the fastest CAGR during the forecast period. Instruments like biopsy needles and bronchoscopes facilitate precise targeting of suspicious lesions within the lung, enhancing the likelihood of obtaining representative tissue samples for diagnosis. These instruments provide a safer approach by minimizing the risk of damaging surrounding healthy lung tissue and other vital organs. Additionally, instrument-based biopsies are typically more cost-effective than open surgical biopsies, making them a more economical option for lung cancer screening.

Lung Cancer Liquid Biopsy Market Key Companies

• Eurofins Scientific
• MDxHealth
• CareDx
• Immucor
• Thermo Fisher Scientific Inc.
• Menarini Silicon Biosystems
• Qiagen
• Guardant Health
• Exact Sciences Corporation
• Myriad Genetics, Inc.
• LungLife AI, Inc.
• Bio-Rad Laboratories
• Agilent Technologies

Lung Cancer Liquid Biopsy Market Segmentation:

By Sample Type

• Blood Sample Based
• Others

By Biomarker

• Circulating Nucleic Acids
• CTC
• Exosomes/Microvesicles
• Circulating Proteins

By Technology

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

By End-use

• Hospitals & Laboratories
• Specialty Clinics
• Academic & Research Centers
• Others

By Clinical Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others

By Product

• Instruments
• Consumables Kits and Reagents
• Software and Services

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)